Double-level indication of globalization effects in portfolio investment models

In this article, to study this problem, proposed a model that describes a double-level mechanism for profit generating. Usage of this model allowed us to set the specificity of the influence of globalization to the main characteristics of portfolio decisions. Based on this specificity was modified the Sharp's diagonal portfolio investment model with the aim of its practical use in the context of globalization. The performed calculations confirmed the validity of the theoretical recommendation

Formation of the investment portfolio on the basis of adaptive-discrete model, considering globalization effects

The article implements the idea of usage of universal properties of an adaptive regression modeling procedure in the processes of making investment solutions with predictor optimality. The necessity of using of universal properties is that the same value in the stock market can be predicted on the basis of inertial changes, and on the basis of discrete, discontinuou

NUMERICAL INVESTIGATION OF MORPHOLOGICAL STABILITY OF MOVING FLUID-FLUID INTERFACE UNDER INITIAL HARMONIC PERTRUBATIONS

Results of numerical calculations of morphological stability of round fluid-fluid interface in Xele-Shaw cell under initial harmonic perturbations are presented.Исследование выполнено при финансовой поддержке РФФИ в рамках научного проекта № 16-31- 00255 мол_а., а также в рамках научного гранта № 1.4539.2017/8.9

ОПЫТ ЛЕЧЕНИЯ ЛИМФОМЫ ХОДЖКИНА РЕФРАКТЕРНОГО ТЕЧЕНИЯ

Background. The use of modern induction chemotherapy programs for primary Hodgkin’s lymphoma allows achievement of high long-term outcomes even in patients with initially poor prognosis. However, the toxicity of treatment is quite high. Despite the effectiveness of chemotherapy, the frequency of relapses and resistant forms varies from 20 to 30 %. In extremely rare cases, the use of intensive chemotherapy regimens, including high-dose chemotherapy, leads to long-term remissions.Description of the clinical case. We present a case of advanced-stage Hodgkin’s lymphoma in a young patient with symptoms of intoxication and adverse risk factors, such as: massive lesion in the mediastinum, increased ES R, infiltration of soft tissues, pleura, pericardium, multiple lesions of both lungs, damage to more than 3 areas of the lymphatic collectors. Given all these factors, the disease prognosis was extremely unfavorable, with a low probability of achieving remission and a high risk of early progression. The use of the intensive EACOPP -14 program allowed the achievement of short-term partial remission. Due to poor treatment tolerance, but taking into account the achievement of a partial response, further treatment was continued using the ABVD chemotherapy regimen. Follow-up examination revealed disease progression. Further courses of chemotherapy using various combinations of chemotherapy drugs resulted in a short-term positive effect with subsequent disease progression. Considering the fact that the disease was resistant to most basic chemotherapeutic agents, immunotherapy with nivolumab (PD -1 inhibitor) was administered. This alternative treatment method allowed the disease to be stabilized.Conclusion. The use of the immunological drug in a patient with chemoresistant Hodgkin’s lymphoma made it possible to stop the progression of the disease and to improve the patient’s quality of life, without significant infectious complications and adverse events.Актуальность. Использование современных программ индукционной химиотерапии при первичной лимфоме Ходжкина позволяет достичь высоких долгосрочных результатов даже у пациентов с исходно неблагоприятным прогнозом. При этом токсичность лечения достаточно высока. Несмотря на эффективность химиотерапии, частота рецидивов и  резистентных форм варьирует от 20 до 30 %. Достижение длительных ремиссий заболевания у части этих пациентов даже с помощью интенсивных режимов химиотерапии, включая высокодозную химиотерапию, крайне затруднительно. Описание клинического случая. Представлен опыт лечения лимфомы Ходжкина у молодой пациентки с распространенной стадией заболевания. В дебюте заболевания определялись симптомы интоксикации и неблагоприятные факторы риска: массивное  образование в средостении, повышенное СОЭ, инфильтрация мягких тканей, плевры, перикарда, множественное поражение обоих легких, поражение более 3 областей лимфатических коллекторов. С учетом всех данных прогноз заболевания был  крайне неблагоприятным с низкой вероятностью достижения ремиссии и высоким  риском раннего прогрессирования. Использование индукционной химиотерапии по интенсифицированной программе «eacopp-14» позволило достичь кратковременной частичной ремиссии. В связи с крайне тяжелой переносимостью лечения и в то же  время с учетом достижения частичного эффекта лечение было продолжено по схеме «aBVd». При очередном промежуточном обследовании констатировано  прогрессирование заболевания. В дальнейшем пациентке суммарно проведено множество курсов химиотерапии с использованием различных сочетаний  химиопрепаратов с кратковременным положительным эффектом и последующим прогрессированием заболевания. Принимая во внимание резистентное к большинству базисных химиопрепаратов течение заболевания, в качестве  альтернативного метода использована иммунотерапия ингибитором pd-1 ниволумабом, которая позволила стабилизировать заболевание.Заключение. Применение лекарственного препарата иммунологической  направленности у пациентки с химиорезистентным течением лимфомы Ходжкина позволило остановить прогрессирование заболевания, улучшить качество жизни  больной без значимых инфекционных осложнений и нежелательных явлений, связанных с применением препарата

Coexistence of axially disturbed spherical particles during their nonequilibrium growth

The initial stage of the loss of the morphological stability by spherical particles during quasi-stationary crystallization has been analyzed numerically. Axial disturbances of arbitrary amplitudes have been considered. Boundaries of the regions of coexistence of different morphologies have been established. The hypothesis that the coexistence regions can be found from the maximum-entropy-production principle has been validated for diffusion growth conditions

Own experience of primary mediastinal B-large cell lymphoma treatment

Due to the relative low incidence of primary mediastinal B-large cell lymphoma (PM BLCL) optimal approaches to its treatment is still not well developed. Possibility to improve PM BLCL clinical outcomes by intensifying induction chemotherapy (CT) and the use of rituximab, the usefulness of high-CT with autologous stem cells transplantation (autologous HSCT) and radiotherapy (RT) is currently being studied.The purpose of this study was to evaluate the efficacy and tolerability of induction therapy MACOP-B with or without rituximab in patients with PM BLCL. 34 patients with PM BLCL, received MACOP-B (n = 10) or R-MACOP-B (n = 24) in P.A. Herzen Moscow Research Institute of Oncology during January 2006 and August 2013, were included in the study. 28 patients (82.4 %) achieved partial/complete remission after MACOP-B ± rituximab completing. In case of insufficient response (large residual tumor) or primary resistance patients received the second line chemotherapy and/or autologous HSCT. 25 patients received radiotherapy for residual tumor mass after CT completion. After completion of full treatment program remission was achieved in total of 32 patients (94.1 %): complete remission in 27 (79.4 %) and partial remission in 5 (14.7 %). Relapse occurred in 3 patients (8.8 %). With a median follow-up of 36.5 months, 3-year disease-free survival was 93 %, eventfree survival – 75 % and overall survival – 90 %. Thus, the “MACOP-B ± rituximab” program was highly effective and acceptable tolerated in PM BLCL patients. The necessity of auto-HSCT and radiotherapy remains debatable.</p

Treatment of primary central nervous system lymphomas

Primary lymphoma of the central nervous system (PLCNS) is a rare form of extranodal lymphoma characterized by an aggressive course. In recent decades, the treatment of this disease has undergone significant changes. Modern treatment of PLCNS consists of two steps – induction and consolidation of remission. Improved overall survival of PLCNS patients was achieved through the use of combined immunochemotherapy regimens with high doses of methotrexate and/or cytarabine, which are currently the standard of induction therapy. High-dose chemotherapy followed by autologous hematopoietic stem cell transplantation at the consolidation stage provides the most complete elimination of the residual tumor clone. The most effective modes of conditioning are those with the inclusion of tiotepa. In elderly and comorbid patients who are not candidates for autologous hematopoietic stem cell transplantation, promising results were obtained while using maintenance therapy with procarbazine or temozolomide, and further researches will allow us to study the effectiveness of monocolonal anti-CD20 antibodies – rituximab and obinutuzumab.Treatment options for patients with relapses and / or refractory forms of PLCNS are limited. Certain successes were obtained with the use of new drugs – ibrutinib, nivolumab, lenalidomide, obinutuzumab